Search | Clinical Trials Finder

Conditions: Diabetic Retinopathy
Interventions: Finerenone (BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more

Conditions: Hypertension (HTN)
Interventions: Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 54
States / cities: Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more

Conditions: Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions: Finerenone, Sotagliflozin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Portland, Oregon

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Epic-Based Clinician Notification, Usual Care; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Diabetic Nephropathies
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 823 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more

Conditions: Type 2 Diabetes, High Blood Pressure
Interventions: Polypill, Combined prescription of the individual medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo, Inspra (eplerenone); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 6,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 107
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Diabetic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 173
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY948862), Others except finerenone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 238,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 57
States / cities: Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Kerendia (Finerenone, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 4,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 38
States / cities: Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY948862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 15,948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Eden Prairie, Minnesota

Conditions: Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 5,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 176
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: Kidney-Protective Therapies Used in Routine Care; Drug
Lead sponsor: Rubix LS; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lawrence, Massachusetts

Conditions: Chronic Kidney Disease, Proteinuria, Children
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Kidney Transplant; Complications
Interventions: Finerenone Oral Tablet, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Heart Failure
Interventions: Finerenone, Empagliflozin; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more

Conditions: Heart Failure, Acute Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 5,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 82
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more

Search by objective public record fields.

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Precision T1D Platform - New Therapies for Cardio-Renal Complications

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Polypill for Prevention of Cardiomyopathy

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Rubix LS Diabetic Kidney Disease (DKD) Registry Study

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes